A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo.

about

A marginal anticancer effect of regorafenib on pancreatic carcinoma cells in vitro, ex vivo, and in vivo.

Item

http://www.wikidata.org/entity/Q38646622

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

A marginal anticancer effect o ...... n vitro, ex vivo, and in vivo.

@en

type

Item

label

A marginal anticancer effect o ...... n vitro, ex vivo, and in vivo.

@en

prefLabel

A marginal anticancer effect o ...... n vitro, ex vivo, and in vivo.

@en

P1476

A marginal anticancer effect o ...... in vitro, ex vivo, and in vivo

@en

P2093

Barbara Mayer

http://www.w3.org/2001/XMLSchema#string

Jens Werner

http://www.w3.org/2001/XMLSchema#string

Li Liu

http://www.w3.org/2001/XMLSchema#string

Nathalie Bauer

http://www.w3.org/2001/XMLSchema#string

Pavel P Philippov

http://www.w3.org/2001/XMLSchema#string

Svetlana Karakhanova

http://www.w3.org/2001/XMLSchema#string

Yifan Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Analyzing real-time PCR data by the comparative C(T) method

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.

Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib.

Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.

P2888

s00210-017-1412-1

P304

1125-1134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00210-017-1412-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

390

http://www.w3.org/2001/XMLSchema#string

P50

Alexandr V Bazhin

P577

2017-08-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1090993535

http://www.w3.org/2001/XMLSchema#string

P698

28779210

http://www.w3.org/2001/XMLSchema#string